Hosted on MSN1mon
Supernus wins FDA approval for Parkinson’s pump on fourth try
Supernus Pharmaceuticals has won US approval for its wearable pump Onapgo (apomorphine hydrochloride ... The company acquired Onapgo, previously known as SPN-830, from US WorldMeds in 2020.
WAVY-TV1mon
Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson’s Disease
formerly known as SPN-830, as the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson’s disease (PD). Supernus will ...
Benzinga.com26d
Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial
formerly known as SPN-830, as the first and only subcutaneous apomorphine infusion device for motor fluctuations in adults with advanced Parkinson’s disease. Supernus will make ONAPGO available ...
The Globe and Mail1mon
Parkinson’s Disease Market is anticipated to Grow at a CAGR of 5.8% During the Study Period (2020-2034) by DelveInsight
Parkinson’s Disease Companies are UCB Biopharma SRL, Novartis, Annovis Bio, Supernus ... SPN-830 is an SC formulation of apomorphine delivered continuously through a portable electronic infusion ...
MarketWatch1mon
Supernus Gets FDA Approval of Onapgo Device for Parkinson's Disease
Supernus Pharmaceuticals has won Food and Drug Administration approval for its Onapgo device to treat patients with Parkinson's disease. Supernus on Tuesday said the FDA green light makes Onapgo ...
manilatimes1mon
Supernus Announces FDA Approval of ONAPGO™ (apomorphine hydrochloride) for Parkinson's Disease
formerly known as SPN-830, as the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson's disease (PD). Supernus will make ...